SWKH · Swk Holdings Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $41.46M | $44.99M | $37.76M | $41.48M | $56.16M | $36.71M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $1.55M | $2.20M | $3.44M | $6.95M | $7.35M | $4.27M |
| SG&A | $14.76M | $11.49M | $11.23M | $12.96M | $13.62M | $10.55M |
| Total Operating Expenses | - | - | ($14.65M) | ($9.97M) | $25.11M | $31.92M |
| D&A | $40.0K | $1.40M | $2.58M | $2.60M | $4.06M | $19.27M |
| Operating Income | $20.27M | $11.59M | $14.61M | $9.49M | $33.01M | $3.67M |
| Interest Expense | $1.10M | $1.10M | $1.85M | $340.0K | $374.0K | $455.0K |
| Income Tax | $22.65M | $4.88M | ($1.27M) | ($4.00M) | $7.08M | ($1.54M) |
| Net Income | ($2.53M) | $13.49M | $15.89M | $13.49M | $5.20M | $5.20M |
| EPS - Basic | ($0.21) | $1.09 | $1.26 | $1.05 | $2.03 | $0.40 |
| EPS - Diluted | ($0.21) | $1.08 | $1.25 | $1.05 | $2.02 | $0.40 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $42.76M | $5.93M | $4.50M | $6.16M | $42.86M | $3.01M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $46.79M | $20.25M | $11.87M | $10.36M | $47.43M | $6.67M |
| Total Assets | $272.42M | $332.24M | $334.25M | $299.62M | $282.67M | $273.90M |
| Current Liabilities | $4.97M | $5.57M | $3.94M | $6.35M | $5.09M | $15.41M |
| Long-term Debt | $32.97M | $32.97M | $32.97M | - | - | - |
| Total Liabilities | $37.32M | $43.55M | $53.94M | $19.69M | $15.43M | $33.39M |
| Stockholders' Equity | $235.10M | $288.69M | $280.31M | $279.93M | $267.24M | $240.51M |
| Retained Earnings | ($4.18B) | ($4.13B) | ($4.14B) | ($4.15B) | ($4.16B) | ($4.19B) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $27.29M | $23.05M | $14.89M | $8.20M | $34.30M | $19.27M |
| Investing Cash Flow | $68.06M | ($10.13M) | ($48.95M) | ($43.55M) | $25.76M | ($35.17M) |
| Financing Cash Flow | ($58.51M) | ($12.22M) | $33.14M | ($1.36M) | ($20.20M) | $7.75M |
| CapEx | $512.0K | $138.0K | $496.0K | $297.0K | $1.08M | $3.94M |
| Free Cash Flow | $26.77M | $22.91M | $14.39M | $7.91M | $33.22M | $15.33M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | 48.9% | 25.8% | 38.7% | 22.9% | 58.8% | 10.0% |
| EBITDA margin | 49.0% | 28.9% | 45.5% | 29.1% | 66.0% | 62.5% |
| Net margin | -6.1% | 30.0% | 42.1% | 32.5% | 9.3% | 14.2% |
| Free cash flow margin | 64.6% | 50.9% | 38.1% | 19.1% | 59.2% | 41.8% |
| FCF / Net income | -10.57 | 1.70 | 0.91 | 0.59 | 6.39 | 2.95 |
| R&D / Revenue | 3.7% | 4.9% | 9.1% | 16.8% | 13.1% | 11.6% |
| SG&A / Revenue | 35.6% | 25.5% | 29.7% | 31.3% | 24.3% | 28.7% |
| Effective tax rate | 112.6% | 26.6% | -8.7% | -42.1% | 57.7% | -41.9% |
| Return on assets | -0.9% | 4.1% | 4.8% | 4.5% | 1.8% | 1.9% |
| Return on equity | -1.1% | 4.7% | 5.7% | 4.8% | 1.9% | 2.2% |
| Return on invested capital | 3.8% | 2.6% | 4.7% | - | - | - |
| Liquidity | ||||||
| Current ratio | 9.41 | 3.64 | 3.01 | 1.63 | 9.31 | 0.43 |
| Quick ratio | 9.41 | 3.64 | 3.01 | 1.63 | 9.31 | 0.43 |
| Cash ratio | 8.60 | 1.07 | 1.14 | 0.97 | 8.41 | 0.20 |
| Leverage | ||||||
| Debt / Equity | 0.14 | 0.11 | 0.12 | - | - | - |
| Debt / Assets | 0.12 | 0.10 | 0.10 | - | - | - |
| Debt / EBITDA | 1.62 | 2.54 | 1.92 | - | - | - |
| Interest coverage | 18.4x | 10.5x | 7.9x | 27.9x | 88.3x | 8.1x |
| Equity multiplier | 1.16 | 1.15 | 1.19 | 1.07 | 1.06 | 1.14 |
| Liabilities / Assets | 0.14 | 0.13 | 0.16 | 0.07 | 0.05 | 0.12 |
| Efficiency | ||||||
| Asset turnover | 0.15 | 0.14 | 0.11 | 0.14 | 0.20 | 0.13 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -7.8% | 19.1% | -9.0% | -26.1% | 53.0% | 19.4% |
| Revenue CAGR (3y) | -0.0% | -7.1% | 0.9% | 10.5% | 29.3% | -0.7% |
| Revenue CAGR (5y) | 2.5% | 7.9% | 7.8% | 2.0% | 20.2% | 9.4% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 75.0% | -20.7% | 54.0% | -71.2% | 800.7% | -78.2% |
| Net income growth (YoY) | - | -15.1% | 17.8% | 159.3% | 0.0% | -78.2% |
| EPS growth (YoY) | - | -13.6% | 19.0% | -48.0% | 405.0% | -78.4% |
| EPS CAGR (3y) | - | -18.8% | 46.2% | -17.2% | 62.6% | 20.3% |
| EPS CAGR (5y) | - | -10.2% | 21.6% | 35.5% | -1.9% | - |
| FCF growth (YoY) | 16.9% | 59.2% | 82.0% | -76.2% | 116.7% | - |
| FCF CAGR (5y) | 11.8% | - | - | - | - | 6.6% |
| Book value growth (YoY) | -18.6% | 3.0% | 0.1% | 4.7% | 11.1% | 1.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$2.15M totalPharmaceutical Development Segment$2.15M · 100.0%
Product / service
$2.15M totalPharmaceutical Development$2.15M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-9.87
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Miscellaneous Business Credit Institution
| Company | Revenue (last FY) | Net margin | ROE |
|---|---|---|---|
| SPFX | $12.47M | 9.7% | 14.3% |
Comparing SWK Holdings Corp against the 1 most active filer in the same SIC group.